Varenicline: Cardiovascular safety

CMAJ. Canadian Medical Association Journal

Volumn 183, Issue 12, 2011, Pages 1406-1408

  Samuels, Larry ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VARENICLINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEART ARRHYTHMIA; HUMAN; LETTER; META ANALYSIS (TOPIC); PERIPHERAL VASCULAR DISEASE; RISK ASSESSMENT; STATISTICAL ANALYSIS; UNITED STATES; UNSTABLE ANGINA PECTORIS;

EID: 80052544340     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.111-2073     Document Type: Letter

References (3)

1. Singh S., Loke Y.K., Spangler J.G., et al. Risk of serious adverse cardiovascular events associated with varenicline: A systematic review and meta-analysis. CMAJ 2011;183:1359-1366
2. Rigotti N.A., Pipe AL, Benowitz Nl, et al. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: A randomized trial. Circulation 2010;121:221-229
3. European Medicine Agency Press Release. European Medicines Agency confirms positive benefit-risk balance for Champix. Benefits as a smokingcessation medicine outweigh slight reported increase in cardiovascular events. Available: www .ema.europa.eu/ema/index.jsp?curl=pages/news -and-events/news/2011/07/news-detail-001314 .jsp&mid= WC0b01ac058004d5c1&murl=menus /news-and-events/news-and-events. jsp&jsenabled =true (accessed 2011 July 25).